ClinicalTrials.Veeva

Menu

Remote Ischemic Preconditioning Induces Myocardial RISK Signaling Pathway in Patients Undergoing Valvular Heart Surgery

Yonsei University logo

Yonsei University

Status and phase

Completed
Phase 4

Conditions

Patients With Elective Aortic Valve Replacement

Treatments

Procedure: Remote ischemic preconditioning at left upper arm
Procedure: Control group

Study type

Interventional

Funder types

Other

Identifiers

NCT01946087
4-2012-0283

Details and patient eligibility

About

The aim of this study is to investigate whether RIPC protects the heart against ischemia reperfusion injury on the concentrically hypertrophied myocardium

Enrollment

79 patients

Sex

All

Ages

20 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients aged ≥20 years with severe degenerative AS presenting concentric remodeling of the LV, who were scheduled for AVR

Exclusion criteria

  • diabetes mellitus,
  • coronary stenosis ≥70%,
  • renal failure (serum creatinine > 2.0 mg/dL),
  • upper arm peripheral vascular disease,
  • LV ejection fraction <50%

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

79 participants in 2 patient groups, including a placebo group

RIPC group
Experimental group
Treatment:
Procedure: Remote ischemic preconditioning at left upper arm
Control group
Placebo Comparator group
Treatment:
Procedure: Control group

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems